6 ALPHA-METHYLPREDNISOLONE

( ARTG ) When oral therapy is not feasible & strength, dosage form & route of administration of drug reasonably lend preparation to treatment of following conditions.‍‍‍‍‍‍​​​‍​​​​​​ Intravenous or intramuscular use only.,Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is drug of choice; mineralocorticoid supplementation may be necessary particularly when synthetic analogues are used). Preoperatively & in event of serious trauma or illness in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or suspected, congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcaemia associated with cancer. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcaemia associated with cancer.,Rheumatic disorders: Adjunctive therapy for short-term administration (to tide patient over an acute episode or exacerbation) in ankylosing spondylitis, psoriatic arthritis, acute & subacute bursitis, synovitis of osteoarthritis, acute non-specific tenosynovitis, epicondylitis, acute gouty arthritis, post-traumatic osteoarthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy).,Collagen disease: During exacerbation or maintenance therapy in selected cases of systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis.,Dermatological diseases: Bullous dermatitis herpetiformis, severe psoriasis, severe seborrhoeic dermatitis, exfoliative dermatitis, pemphigus, mycosis fungoides, severe erythema multiforme (Stevens Johnson syndrome).,Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in bronchial asthma, drug hypersensitivity reactions, contact dermatitis, urticarial transfusion reactions, atopic dermatitis, serum sickness, seasonal or perennial allergic rhinitis, acute non-infectious laryngeal oedema (adrenaline is drug of first choice).,Ophthalmic diseases: Severe acute & chronic allergic & inflammatory processes involving eye, such as allergic corneal marginal ulcers, , allergic conjunctivitis, chorioretinitis, anterior segment inflammation, herpes zoster ophthalmicus, iritis iridocvclitis, diffuse posterior uveitis & choroiditis, keratitis, optic neuritis, sympathetic ophthalmia.,Gastrointestinal diseases: To tide patient over a critical period of disease in ulcerative colitis (systemic therapy), regional enteritis (systemic therapy).,Respiratory diseases: Symptomatic sarcoidosis, berylliosis, aspiration pneumonitis, Loeffler's syndrome not manageable by other means, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy.,Haematologic disorders: Idiopathic thrombocytopenic purpura in adults (intravenous only; intramuscular is contraindicated), secondary thrombocytopenia in adults, acquired (autoimmune) haemolytic anaemia, erythroblastopenia (red blood cell anaemia), congenital (erythroid) hypoplastic anaemia.,Neoplastic diseases: Palliative management of leukaemias & lymphomas in adults, acute leukaemia of childhood.,Oedematous states: To induce diuresis or remission of proteinuria in nephrotic syndrome, without uraemia, of idiopathic type or due to lupus erythematosus.,Nervous system: Acute exacerbations of multiple sclerosis.,Miscellaneous: Tuberculous meningitis with subarachnoid or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurological or myocardial involvement. METHYLPRED is beneficial as adjunctive therapy in treatment of AIDS affected patients with moderate to severe P. carinii pneumonia when given within first 72hrs of initial antipneumocystis treatment.